Inflammation Center, Department of Infectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Meilahti Infectious Diseases and Vaccine Research Center, MeiVac, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Euro Surveill. 2021 Sep;26(39). doi: 10.2807/1560-7917.ES.2021.26.39.2001360.
BackgroundWhile 20-80% of regular visitors to (sub)tropical regions become colonised by extended-spectrum β-lactamase-producing (ESBL-PE), those hospitalised abroad often also carry other multidrug-resistant (MDR) bacteria on return; the rates are presumed to be highest for interhospital transfers.AimThis observational study assessed MDR bacterial colonisation among patients transferred directly from hospitals abroad to Helsinki University Hospital. We investigated predisposing factors, clinical infections and associated fatalities.MethodsData were derived from screening and from diagnostic samples collected between 2010 and 2019. Risk factors of colonisation were identified by multivariable analysis. Microbiologically verified symptomatic infections and infection-related mortality were recorded during post-transfer hospitalisation.ResultsColonisation rates proved highest for transfers from Asia (69/96; 71.9%) and lowest for those within Europe (99/524; 18.9%). Of all 698 patients, 208 (29.8%) were colonised; among those, 163 (78.4%) carried ESBL-PE, 28 (13.5%) MDR species, 25 (12.0%) meticillin-resistant , 25 (12.0%) vancomycin-resistant , 14 (6.7%) carbapenemase-producing , and 12 (5.8%) MDR ; 46 strains tested carbapenemase gene-positive. In multivariable analysis, geographical region, intensive care unit (ICU) treatment and antibiotic use abroad proved to be risk factors for colonisation. Clinical MDR infections, two of them fatal (1.0%), were recorded for 22 of 208 (10.6%) MDR carriers.ConclusionsColonisation by MDR bacteria was common among patients transferred from foreign hospitals. Region of hospitalisation, ICU treatment and antibiotic use were identified as predisposing factors. Within 30 days after transfer, MDR colonisation manifested as clinical infection in more than 10% of the carriers.
在前往(亚热带)地区的常规访客中,有 20-80%会定植产超广谱β-内酰胺酶的(ESBL-PE),而那些在国外住院的人在返回时通常也会携带其他多种耐药(MDR)细菌;医院间转院的患者携带这些细菌的比例最高。
本观察性研究评估了直接从国外医院转入赫尔辛基大学医院的患者的 MDR 细菌定植情况。我们研究了定植的相关危险因素、临床感染和相关死亡率。
数据来自 2010 年至 2019 年期间的筛查和诊断样本。通过多变量分析确定定植的危险因素。记录转院后住院期间经微生物学证实的有症状感染和感染相关死亡率。
从亚洲(69/96;71.9%)和欧洲(99/524;18.9%)转院的患者的定植率最高。在所有 698 名患者中,有 208 名(29.8%)定植;其中,163 名(78.4%)携带 ESBL-PE,28 名(13.5%)携带 MDR 细菌,25 名(12.0%)携带耐甲氧西林,25 名(12.0%)携带耐万古霉素,14 名(6.7%)携带产碳青霉烯酶,12 名(5.8%)携带 MDR 细菌;46 株检测出携带碳青霉烯酶基因。多变量分析表明,地理区域、重症监护病房(ICU)治疗和国外使用抗生素是定植的危险因素。在 208 名 MDR 定植者中,有 22 名(10.6%)发生了临床 MDR 感染,其中 2 例死亡(1.0%)。
从国外医院转入的患者中,MDR 细菌定植很常见。住院地点、入住 ICU 和抗生素使用被确定为定植的危险因素。在转院后 30 天内,超过 10%的定植者出现 MDR 感染的临床症状。